cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.12530719
title: Datasets related to the article "Blood analysis parameters genetically associated with longevity in jumping horses". Complete data sets of blood parameters measurements, pedigree and identity of the measured horses
DOI: 10.5281/zenodo.12531357
title: Datasets related to the article "Blood analysis parameters genetically associated with longevity in jumping horses". Complete data sets of blood parameters measurements, pedigree and identity of the measured horses
DOI: 10.7910/dvn/bet7vi/bdqpea
title: ICU_trainingdata_NI-.tab

description: :unav
DOI: 10.7910/dvn/bet7vi/33isal
title: ICU_validationdata_NI-.tab

description: :unav
DOI: 10.7910/dvn/8oval6/ainxqy
title: LIS_replication_data.tab

description: :unav
DOI: 10.7910/dvn/8oval6/c8iygb
title: Macro Analysis_Replication.do

description: :unav
DOI: 10.7910/dvn/8oval6/pplmb5
title: CSES_replication_data.tab

description: :unav
DOI: 10.7910/dvn/8oval6/2xifen
title: Micro Analysis_Replication.do

description: :unav
DOI: 10.7910/dvn/8oval6/a7tilv
title: Median_to_mean_income_1985_2010.tab

description: :unav
DOI: 10.7910/dvn/8oval6/fpv3ne
title: README.rtf

description: :unav
DOI: 10.7910/dvn/8oval6/jctmc0
title: micro data - web appendix B.tab

description: :unav
DOI: 10.7910/dvn/8oval6/zhm5mu
title: Part I_replication_data.tab

description: :unav
DOI: 10.7910/dvn/8oval6/7rnbwe
title: Simulation_9095100.tab

description: :unav
DOI: 10.7910/dvn/8oval6/agerye
title: Web Appendix_Replication.do

description: :unav
DOI: 10.7910/dvn/8oval6/okpvni
title: Simulation_7585100.tab

description: :unav
DOI: 10.7910/dvn/8oval6/yvppv1
title: Simulation_Replication.do

description: :unav
DOI: 10.7910/dvn/vciw2i/0rgwco
title: appendix.tar

description: Replication files for appendix
DOI: 10.7910/dvn/vciw2i/6ssziv
title: README.pdf

description: :unav
DOI: 10.7910/dvn/vciw2i/l2qmc8
title: paper.tar

description: Replication files for main paper
DOI: 10.7910/dvn/swqn4b
title: Raw Data for: Language-based response bias in the stream/bounce judgment

description: Raw data.
DOI: 10.7910/dvn/syenh1/cm872f
title: 000_Staff_questionnaire_SK.pdf

description: :unav
DOI: 10.7910/dvn/syenh1/jhtbyy
title: 004_Bangladesh_A&T_BaselineSurvey_Report.pdf

description: :unav
DOI: 10.7910/dvn/syenh1/ncccpt
title: 002_SK_codebook.pdf

description: :unav
DOI: 10.7910/dvn/syenh1/tuyg5c
title: 001_BD_P1_BS_2010_SK_final.tab

description: :unav
DOI: 10.7910/dvn/syenh1/ye2uqf
title: 003_SK_value_labels.pdf

description: :unav
DOI: 10.7910/dvn/elwyv6
title: Replication Data for: Description of the Martensitic Transformation Resulting From the Minimization of Atomic Displacements

description: The files present the evolution of the crystal structure during the martensitic transformation in the POSCAR format.
DOI: 10.7910/dvn/5vwkmc/l20yqj
title: dwarf_label_info.tab

description: Contains the pivot, scale, and column name of each label for the dwarf model
DOI: 10.7910/dvn/5vwkmc/qto5ne
title: giant_labels.tab

description: Contains the pivot, scale, and column name of each label for the giant model
DOI: 10.7910/dvn/5vwkmc/sjfi9v
title: dwarf_model.tab

description: The dwarf model coefficients. Can be loaded into Julia with Matrix(CSV.read(models/dwarf_model.csv))
DOI: 10.7910/dvn/5vwkmc/3ngmbu
title: inferred_labels.h5

description: Per-spectrum inferred parameters and abundances
DOI: 10.7910/dvn/5vwkmc/adndgh
title: inferred_labels_unique.h5

description: Per-star inferred parameters and abundances. Corresponds to Table 1 in Wheeler+ 2020.
DOI: 10.7910/dvn/5vwkmc/jaui6m
title: giant_model.tab

description: The giant model coefficients. Can be loaded into Julia with Matrix(CSV.read(models/giant_model.csv))
DOI: 10.7910/dvn/5vwkmc/rcdv8t
title: wl_grid.jld2

description: The wavelengths to which each LAMOST spectrum has been (linearly) interpolated
DOI: 10.7910/dvn/5vwkmc/sf3ca5
title: training_set.tab

description: The training set.
DOI: 10.7910/dvn/cojzmq/37d4mh
title: 12558P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/4th1hn
title: 12550P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/5feekp
title: 12551P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/eqrwaj
title: 1254PP.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/k3tklw
title: 12561P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/n8zvii
title: 12552P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/2bhv7g
title: 12872P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/6uc5ac
title: 12851P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/g1uxfl
title: 12852P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/jpf4lz
title: 12872_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/l2luhu
title: 12874P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/azc9d2
title: 12879P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/cqquza
title: 12876P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/eanfix
title: 12883P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/ma0emj
title: 12882P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/w3wkzc
title: 12877P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/zwvlhg
title: 12884P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/aarott
title: 13155P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/fbyale
title: 13120P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/gjydjs
title: 13149P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/gnuz2x
title: 12900P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/pmzvfn
title: 12900_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/rzjewz
title: 12902P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/8vphoh
title: 13168P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/hzg64u
title: 13164P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/n7jd4g
title: 13174P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/uo0w2q
title: 13161P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/v7zohn
title: 13171P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/ybdg10
title: 13166P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/1y5dfn
title: 13181P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/ebcvpw
title: 13182P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/eh66ip
title: 13177P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/lgas7p
title: 13184P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/qy8iqg
title: 13176P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/annldi
title: 13202P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/crubds
title: 13185P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/h8igg9
title: 13394_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/kkcpph
title: 13391P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/qikfgu
title: 13392P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/tdx341
title: 13393P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/ub6que
title: 13390P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/bbnuad
title: 13394P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/ji4aon
title: 13396__P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/m1bdjx
title: 13395P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/oii3oj
title: 13396_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/zjybyg
title: 13396P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/b0b8cn
title: 13397_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/dgsxlv
title: 13400___P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/hmxmlp
title: 13398P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/hsy7rd
title: 13399P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/wx5csh
title: 13398_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/zg7igm
title: 13397P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/4rjssb
title: 13400P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/63834g
title: 13400_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/eermf6
title: 13401P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/jajxb5
title: 13400__P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/rkr9ry
title: 13401_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/tv1lqb
title: 13402_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/4b50rx
title: 13418P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/bxkdtb
title: 13417P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/ctymb6
title: 13402P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/dkpksv
title: 13415P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/g2kdaa
title: 13412P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/ky1m3j
title: 13416P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/aztimn
title: 13422P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/ctdgti
title: 13420_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/egg0bm
title: 13421P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/iu5zwc
title: 13419P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/libpw3
title: 13420P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/2da4zr
title: 13423P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/bsvgib
title: 13425P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/c6fiaw
title: 13426_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/tdfbsx
title: 13424_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/w0bn2i
title: 13426P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/zxoj7r
title: 13424P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/c1ex1t
title: 13648P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/ldp88u
title: 13481P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/lie6n6
title: 13430P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/nzfz46
title: 13429P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/wldueu
title: 13428P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/yycs2n
title: 13427P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/7dcgpb
title: 13780P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/gwfyte
title: 13782P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/mtsijg
title: 13769P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/p4cquy
title: 13787P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/zls57n
title: 13788P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/zzze4m
title: 13784P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/67xnof
title: 13792P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/hcoq4q
title: 13790P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/lqu7j1
title: 13798P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/lzhioz
title: 13794P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/scfr4e
title: 13791P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/0pkyz2
title: Consent_form.doc

description: :unav
DOI: 10.7910/dvn/cojzmq/e4pxj9
title: DIB_tables.docx

description: This explanation is related to two Excel files we previously uploaded as tongue_data_sample-1.xlsx and sample of unlabeled data-1.csv.
DOI: 10.7910/dvn/cojzmq/eixzhw
title: 13800P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/oxzm2c
title: 13799P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/t9hjuj
title: 13799_P.jpg

description: :unav
DOI: 10.7910/dvn/cojzmq/xibeq6
title: DIB_figures.docx

description: :unav
DOI: 10.7910/dvn/cojzmq/hhisot
title: IRB_approval.pdf

description: :unav
DOI: 10.7910/dvn/cojzmq/x5mt7j
title: Letter_of_support.pdf

description: :unav
DOI: 10.6084/m9.figshare.26379859
title: Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer

description: <b>Aim:</b> To describe treatment-induced toxicities (TITs) and associated factors in Zimbabwean cancer patients receiving cisplatin. <b>Methods:</b> In total, 252 Zimbabwean women with cervical cancer, receiving cisplatin were followed up over 12 months for TITs and disease status. <b>Results:</b> Peripheral neuropathy (70%) and ototoxicity (53%) were most prevalent. Advanced disease (OR = 1.3; 95% CI = 1.1–1.5; p = 0.02), pain comedications (OR = 1.3; 95% CI = 1.1–1.5; p = 0.03), alcohol (OR = 2.8; 95% CI = 1.1–7.5; p = 0.04) and comorbidities (OR = 1.2; 95% CI = 1.1–1.4; p = 0.04) increased peripheral neuropathy and ototoxicity risk. Older age increased risk of disease progression (OR = 1.9; 95% CI = 1.4–3.0; p = 0.033). <b>Conclusion:</b> High peripheral neuropathy and ototoxicity prevalence were observed, which are not routinely monitored in Zimbabwe. There is a need for capacity building to incorporate comprehensive TIT testing and optimize cancer care in Zimbabwe. Cancer treatment has side effects, also known as treatment-induced toxicities (TITs), that can lead to death if not management properly. African populations are more likely to develop TITs, however, not many studies research on TITs in Africans and why they are more prone to TITs. This study followed up 252 Zimbabwean women with cervical cancer, over 12 months for TITs and found that loss of sensation and ear complications most commonly occurred after treatment. Advanced disease, prescribed pain medication, alcohol consumption history and underlying diseases such as diabetes increased likelihood of TITs, while older age increased risk of unresponsive cancer. This study highlights a need to incorporate comprehensive monitoring for TITs for at-risk individuals toward improving cancer care. Peripheral neuropathy and ototoxicity are common in Zimbabwean cancer patients, even though they are not routinely monitored in oncology facilities. Clinical factors such as comorbid conditions, pain co-medications and high cisplatin dose increase the risk of developing treatment-induced toxicities (TITs). High BMI was a predictor of peripheral neuropathy development. Lifestyle factors such as history of alcohol consumption can increase the risk of treatment-induced toxicities. In this study, HIV was not a risk factor for any of the TITs and treatment outcomes such as relapse, disease progression and mortality. Older patients are more prone to poor prognosis compared with younger patients highlighting a need for cancer screening even beyond the prescribed age of 40 years. Comprehensive TIT monitoring should be implemented in Zimbabwe primary care for cancer patients, to include peripheral neuropathy and ototoxicity, toward improving patient management. More studies to describe TITs in low-resource settings such as Zimbabwe are required in order to personalize medicine.
DOI: 10.6084/m9.figshare.26379859.v1
title: Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer

description: <b>Aim:</b> To describe treatment-induced toxicities (TITs) and associated factors in Zimbabwean cancer patients receiving cisplatin. <b>Methods:</b> In total, 252 Zimbabwean women with cervical cancer, receiving cisplatin were followed up over 12 months for TITs and disease status. <b>Results:</b> Peripheral neuropathy (70%) and ototoxicity (53%) were most prevalent. Advanced disease (OR = 1.3; 95% CI = 1.1–1.5; p = 0.02), pain comedications (OR = 1.3; 95% CI = 1.1–1.5; p = 0.03), alcohol (OR = 2.8; 95% CI = 1.1–7.5; p = 0.04) and comorbidities (OR = 1.2; 95% CI = 1.1–1.4; p = 0.04) increased peripheral neuropathy and ototoxicity risk. Older age increased risk of disease progression (OR = 1.9; 95% CI = 1.4–3.0; p = 0.033). <b>Conclusion:</b> High peripheral neuropathy and ototoxicity prevalence were observed, which are not routinely monitored in Zimbabwe. There is a need for capacity building to incorporate comprehensive TIT testing and optimize cancer care in Zimbabwe. Cancer treatment has side effects, also known as treatment-induced toxicities (TITs), that can lead to death if not management properly. African populations are more likely to develop TITs, however, not many studies research on TITs in Africans and why they are more prone to TITs. This study followed up 252 Zimbabwean women with cervical cancer, over 12 months for TITs and found that loss of sensation and ear complications most commonly occurred after treatment. Advanced disease, prescribed pain medication, alcohol consumption history and underlying diseases such as diabetes increased likelihood of TITs, while older age increased risk of unresponsive cancer. This study highlights a need to incorporate comprehensive monitoring for TITs for at-risk individuals toward improving cancer care. Peripheral neuropathy and ototoxicity are common in Zimbabwean cancer patients, even though they are not routinely monitored in oncology facilities. Clinical factors such as comorbid conditions, pain co-medications and high cisplatin dose increase the risk of developing treatment-induced toxicities (TITs). High BMI was a predictor of peripheral neuropathy development. Lifestyle factors such as history of alcohol consumption can increase the risk of treatment-induced toxicities. In this study, HIV was not a risk factor for any of the TITs and treatment outcomes such as relapse, disease progression and mortality. Older patients are more prone to poor prognosis compared with younger patients highlighting a need for cancer screening even beyond the prescribed age of 40 years. Comprehensive TIT monitoring should be implemented in Zimbabwe primary care for cancer patients, to include peripheral neuropathy and ototoxicity, toward improving patient management. More studies to describe TITs in low-resource settings such as Zimbabwe are required in order to personalize medicine.
DOI: 10.6084/m9.figshare.27275336
title: Trends and frontiers of maintenance therapy for ovarian cancer over the past 20 years: a bibliometric analysis

description: <b>Aim:</b> To summarize and analyze the research trends and frontiers in maintenance therapy for ovarian cancer over the past 20 years. <b>Methods:</b> Relevant articles were identified in Web of Science, and analyzed using CiteSpace and Excel. <b>Results:</b> 1204 articles from 61 countries led by the USA and England were included. 6821 authors, 2345 institutions and 292 journals have participated in the publication of papers, but the collaboration between them was not very close. The annual publication volume has increased significantly since 2015. Drug combination therapy, genetic testing, management of adverse reaction and prognostic factors are research trends and frontiers of this field. <b>Conclusion:</b> This is the first bibliometric research in this field, which can provide some references for researchers. This is the first bibliometric research about maintenance therapy for ovarian cancer. A total of 1204 articles were collected in this study from January 2000 to September 2022, with 728 articles and 476 reviews. Since 2015, the number of articles has rapidly increased, and will continue to grow, indicating that maintenance therapy for ovarian cancer is receiving increasing attention from scholars. The top two most cited publications focused on Niraparib and Olaparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. The USA and England were the top two ranked countries with the most publications. However, less cooperation was observed among institutions from these countries. The USA and Univ Texas MD Anderson Canc Ctr were the most impact country and institution, respectively. Chemotherapy drugs alone, PARP inhibitors alone, or antiangiogenesis drugs alone were used for 1st-line, 2rd-line, or late-line maintenance therapy are the research foundation. Drug combination maintenance therapy based on effective monotherapy, as well as genetic testing, management of adverse reaction and prognostic factors are research trends and frontiers of maintenance therapy for ovarian cancer.
DOI: 10.6084/m9.figshare.27275336.v1
title: Trends and frontiers of maintenance therapy for ovarian cancer over the past 20 years: a bibliometric analysis

description: <b>Aim:</b> To summarize and analyze the research trends and frontiers in maintenance therapy for ovarian cancer over the past 20 years. <b>Methods:</b> Relevant articles were identified in Web of Science, and analyzed using CiteSpace and Excel. <b>Results:</b> 1204 articles from 61 countries led by the USA and England were included. 6821 authors, 2345 institutions and 292 journals have participated in the publication of papers, but the collaboration between them was not very close. The annual publication volume has increased significantly since 2015. Drug combination therapy, genetic testing, management of adverse reaction and prognostic factors are research trends and frontiers of this field. <b>Conclusion:</b> This is the first bibliometric research in this field, which can provide some references for researchers. This is the first bibliometric research about maintenance therapy for ovarian cancer. A total of 1204 articles were collected in this study from January 2000 to September 2022, with 728 articles and 476 reviews. Since 2015, the number of articles has rapidly increased, and will continue to grow, indicating that maintenance therapy for ovarian cancer is receiving increasing attention from scholars. The top two most cited publications focused on Niraparib and Olaparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. The USA and England were the top two ranked countries with the most publications. However, less cooperation was observed among institutions from these countries. The USA and Univ Texas MD Anderson Canc Ctr were the most impact country and institution, respectively. Chemotherapy drugs alone, PARP inhibitors alone, or antiangiogenesis drugs alone were used for 1st-line, 2rd-line, or late-line maintenance therapy are the research foundation. Drug combination maintenance therapy based on effective monotherapy, as well as genetic testing, management of adverse reaction and prognostic factors are research trends and frontiers of maintenance therapy for ovarian cancer.
DOI: 10.15468/dl.sxctjg
title: Occurrence Download

description: A dataset containing 8783 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Spain",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Mustela vison Schreber, 1777"
 ]
}

 The dataset includes 8783 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0029431-241007104925546/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.g9h5ss
title: Occurrence Download

description: A dataset containing 8301 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Spain",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Neovison vison (Schreber, 1777)"
 ]
}

 The dataset includes 8301 records from 11 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0029432-241007104925546/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.7910/dvn/crqfbo/g9hqv6
title: 01EE_List of dishes and ingredients from expert elicitation workshop.tab

description: :unav
DOI: 10.7910/dvn/srm5ga/ylvsca
title: 05Database_of eastern_indian_dishes.tab

description: :unav
DOI: 10.7910/dvn/nfjz7z/0bomvh
title: 06Bexpt_01surveydata-1.tab

description: Data on household and individual survey using the accompanying sheets
DOI: 10.7910/dvn/nfjz7z/cotorf
title: 06Bexpt_03dishdatabase-1.tab

description: Dishes in the food application classified into food group along with its cost and nutritional content
DOI: 10.7910/dvn/nfjz7z/j96xdz
title: 06Bexpt_02foodappdata-1.tab

description: data collected using the food application